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Body mass index (BMI) and breast cancer biomarkers (BCBs) such as 
resistin, leptin adiponectin, monocyte chemoattractant protein-1 (MCP-1) 
and homeostasis model assessment of insulin resistance (HOMA-IR) are 
highly associated with each other. The report has focused the inter-rela-
tionship between BMI and BCBs based on probabilistic modeling. It has 
been shown that mean BMI is directly associated with leptin (P<0.0001) 
and MCP-1 (P=0.0002), while it is inversely associated with adiponectin 
(P=0.0003), HOMA-IR (P<0.0001), and it is higher for healthy women 
(P=0.0116) than breast cancer women. In addition, variance of BMI 
is inversely associated with resistin (P=0.1450). On the other hand, 
mean MCP-1 is directly associated with BMI (P<0.0001). Mean re-
sistin is directly associated with the interaction effect of BMI and leptin 
(BMI*Leptin) (P=0.0415), while its variance is directly associated with 
BMI (P=0.0942), and it is inversely associated with BMI*Adiponectin 
(P=0.1518). Leptin is directly associated with BMI (P<0.0001). Also 
adiponectin is inversely associated with BMI (P<0.0001), BMI*Leptin 
(P=0.1729), while it is directly associated with Age*BMI (P=0.0017) 
and BMI*Resistin (P=0.0615). It can be concluded that BMI and BCBs 
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1. Introduction
BMI has been a fundamental psychosocial issue among human beings for millennia. It is a com-posite measure of height and weight, which is 
defined as BMI= Weight(kg) / Height(m2).  An individual 
fatness index is measured by BMI.  It is considered as the 
risk factor for the growth of many diseases such as breast 
cancer, diabetes, cardiovascular diseases, etc. [1-5]. In gen-
eral, BMI less than or equal to 25 kg/m2 is treated as the 
normal, otherwise it is considered as obesity. 
Excess weight has been associated with a variety of 
cancers such as postmenopausal breast, colon, renal, 
esophageal, endometrial etc. The International Research 
Agency on Cancer has predicted that BMI causes 9% of 
breast cancer, 25% of renal cancer, 11% of colon cancer, 39% 
of endometrial cancer, and 37% of esophageal cancer [6]. Calle et 
al. [7] pointed that BMI was associated with a greater risk 
of death from 14 cancers such as esophagus, liver, colon 
and rectum, gallbladder, kidney, pancreas, non-Hodgkin 
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lymphoma, stomach, multiple myeloma, breast, prostate, 
cervix, uterus, and ovary, and it was predicted that BMI 
may account for 20% of all cancer deaths in women and 
14% in men [7]. 
BMI is a well-known risk factor for postmenopausal 
breast cancer, whereas debatable outcomes have been pre-
sented in premenopausal women [8-10]. A large sample me-
ta-analysis reported an inverse association between BMI 
and the chance of premenopausal breast cancer [11]. Re-
cently, two large prevention data studies have shown that 
premenopausal women with higher BMI are at increased 
risk for growing breast cancer [12,13].
The relationships between BMI and BCBs are still 
contradictable [8,9,11,14-16]. These can be studied based on 
statistical modeling of BMI on the BCBs such as leptin, 
resistin, adiponectin and MCP-1 and other explanatory 
variables. Again, each BCB should be modeled on BMI 
and other explanatory variables. The current report fo-
cuses the associations between BMI and BCBs based on 
modeling of BMI, MCP-1, adiponection, resistin, and 
leptin.  For a data set given in [17,18], these models have 
been studied in [19-23]. From these models, the relationships 
between BMI and BCBs are reported in the current article.
2. Materials and Methods 
2.1 Materials
The data set can be found in the UCI Machine Learning 
Repository, and its detailed description is given in [17,18]. 
For immediate using of the covariates in the report, these 
are restated as BMI (kg/m2), Age, HOMA-IR, Insulin (μU/
mL), Glucose (mg/dL), Adiponectin (μg/mL), Resistin (ng/
mL), MCP-1, Leptin(ng/mL), Types of Patient (TYOP) 
(1=healthy controls; 2=patients).
2.2 Statistical Methods
The considered data set given in [17,18] is a multivariate data set. 
The interested responses are BMI, resistin, MCP-1, adiponec-
tin, leptin which are all positive continuous heterogeneous and 
non-normally distributed. These are required to be modeled 
herein. These can be appropriately modeled using joint gener-
alized linear models (JGLMs) adopting both the Log-normal 
and Gamma distributions, which are clearly given in [24-26]. Both 
the JGLMs under the Log-normal and Gamma distributions are 
very shortly given in recent articles [22-23], which are not repro-
duced herein. For more discussions on JGLMs, readers can 
visit [24,25]. 
2.3 Statistical and Graphical Analysis
For ready reference, first we examine BMI model on age, 
insulin, glucose, and BCBs. The detailed analysis is giv-
en by Das et al. [19]. It is mentioned herein that BMI and 
BCBs such as MCP-1, resistin, leptin and adiponectin can 
be modeled adopting JGLMs under both the Log-normal 
& Gamma distributions [24-26]. Log-normal JGLMs fit of 
BMI is better than the Gamma fit, which is presented in 
Table 1, and its fitting diagnostic is revealed in Figure 1. 
Figure 1(a) displays the absolute residuals plot against 
the predicted BMI values, which is closely a flat straight 
line, implying that variance is constant with the running 
means. Figure 1(b) represents the normal probability plot 
of the fitted BMI mean Log-normal model in Table 1. No 
lack of fit is identified in both the figures. So, Log-normal 
fitted BMI model (Table 1) is an approximate form of its 
true model.  Fitted BMI mean & dispersion models are as 
follows:
Fitted Log-normal BMI mean ( Ẑ ) model (from Table 1) is
Ẑ = Log(BMI)= 3.0370 - 0.0421 HOMA-IR + 0.0015 
Glucose + 0.0123 Insulin - 0.0068 Adiponectin + 0.0001 
MCP-1 + 0.0053 Leptin - 0.0708 TYOP, 
and the BMI fitted Log-normal variance ( 2σ̂ )  model is 




       
(b)
Figure 1. For the joint Log-normal BMI fitted models 
(Table 1), the (a) absolute residuals plot against the fitted 
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Table 1. Results for mean and dispersion models for BMI from Log-Normal and Gamma fit
Model Covariates
Log-normal Gamma
Estimate s.e. t-value P-Value Estimate s.e. t-value P-Value
Mean
Constant 3.0370 0.08363 36.3122 <0.0001 3.0460 0.08367 36.4013 <0.0001
Glucose (x3) 0.0015 0.00084 1.7961 0.0753 0.0016 0.00085 1.8502 0.0670
Insulin (x4) 0.0123 0.00318 3.8502 0.0002 0.0121 0.00318 3.8281 0.0002
HOMA-IR (x5) -0.0421 0.01033 -4.0823 <0.0001 -0.0421 0.01019 -4.1333 <0.0001
Leptin (x6) 0.0053 0.00063 8.2341 <0.0001 0.0052 0.00065 8.0953 <0.0001
Adiponectin (x7) -0.0068 0.00184 -3.7363 0.0003 -0.0068 0.00186 -3.6552 0.0004
MCP-1  (x9) 0.0001 0.00005 3.8724 0.0002 0.0001 0.00006 3.7272 0.0003
Patient’s typ (Fx10) -0.0708 0.02758 -2.5681 0.0116 -0.0699 0.02768 -2.5241 0.0130
Dispersion
Constant -4.445 0.7261 -6.1224 <0.0001 -4.358 0.7167 -6.0821 <0.0001
Age (x1) 0.015 0.0107 1.3652 0.1751 0.013 0.0108 1.2652 0.2085
Resistin (x8) -0.019 0.0132 -1.4683 0.1450 -0.020 0.0134 -1.5082 0.1344
Insulin (x4) -0.018 0.0156 -1.1784 0.2413 -0.019 0.0157 -1.2233 0.2239
AIC= 613.9 AIC=615.062
Table 2. Results for mean & dispersion models for MCP-1 from Log-Normal and Gamma fit
Model Covariate
Gamma Model Log-normal Model
estimate s.e. t-value P-value Estimate s.e. t-value P-value
Mean
Model
Constant 5.1791 0..27784 18.641 <0.0001 4.9439 0.28594 17.290 <0.0001
BMI (x2) 0.0455 0.01066 4.265 <0.0001 0.0465 0.01101 4.226 <0.0001
Insulin (x4) -0.0265 0.00449 -5.900 <0.0001 -0.0225 0.00494 -4.566 <0.0001
Leptin (x6) -0.0192 0.00336 -5.730 <0.0001 -0.0174 0.00345 -5.038 <0.0001
Insulin *Leptin 0.0009 0.00017 5.458 <0.0001 0.0009 0.00018 4.846 <0.0001
Resistin (x8) 0.0220 0.00348 6.327 <0.0001 0.0239 0.00345 6.923 <0.0001
Dispersion
Model
Constant 0.7374 1.5228 0.484 0.6293 1.0110 1.5513 0.652 0.5158
Age (x1) -0.0293 0.0161 -1.826 0.0706 -0.0328 0.0156 -2.097 0.0383
Insulin (x4) -0.0868 0.0733 -1.184 0.2390 -0.0613 0.0720 -0.851 0.3966
Age* Insulin 0.0051 0.0016 3.098 0.0025 0.0054 0.0015 3.488 0.0008
HOMA-IR (x5) -0.8286 0.2928 -2.830 0.0055 -0.9607 0.2825 -3.400 0.0009
Glucose (x3) 0.0053 0.0144 0.371 0.7113 0.0069 0.0143 0.483 0.6300
Leptin (x6) -0.0997 0.0421 -2.365 0.0198 -0.1177 0.0416 -2.826 0.0056
Glucose* Leptin 0.0007 0.0004 1.756 0.0819 0.0008 0.0004 2.091 0.0388
Resistin (x8) -0.0405 0.0227 -1.781 0.0777 -0.0524 0.0224 -2.332 0.0215
Leptin*Resistin 0.0010 0.0004 2.411 0.0176 0.0013 0.0004 3.114 0.0024
AIC=1572.816 AIC=1575
Biomarker MCP-1 analysis is given by Kim et al. [20], 
and for ready reference it is reproduced in Table 2.  Fitted 
MCP-1 mean & dispersion models are as follows:
MCP-1Gamma fitted mean ( µ̂ ) model (from Table 2) is
µ̂ = exp(5.1791 - 0.0265 Insulin +  0.0455 BMI - 0.0192 
Leptin  + 0.0220 Resistin + 0.0009 Insulin*Leptin ),  
and MCP-1Gamma fitted dispersion ( 2σ̂ )  model (from 
Table 2) is   
2σ̂ = exp(0.7374 - 0.0868 Insulin - 0.0293 Age + 0.0051 
Age*Insulin + 0.0053 Glucose - 0.8286 HOMA-IR - 
0.0997 Leptin - 0.0405 Resistin + 0.0007 Glucose*Leptin 
+ 0.0010 Leptin*Resistin). 
Biomarker adiponectin analysis is given by Das and 
Lee [21], and for ready reference it is reproduced in Table 
3. Fitted adiponectin  mean & dispersion models are as 
follows.
Adiponectin Gamma fitted mean ( µ̂ ) model (from Ta-
ble 3) is
µ̂ = exp( 6.7778 - 0.1475 BMI - 0.0617 Age + 0.0020 
Age*BMI - 0.0662 Resistin + 0.0282 Leptin + 0.0018 
BMI*Resistin - 0.0008 BMI*Leptin),  
and Adiponectin Gamma fitted variance ( 2σ̂ )  model 
(from Table 3) is   
2σ̂ =  exp(-2.318 + 0.017Age). 
DOI: https://doi.org/10.30564/jor.v2i1.2007
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Table 3. Results for mean and dispersion models for Adiponectin from Log-Normal and Gamma fit
Model Covariate
Log-normal fit Gamma fit
Estimate S.E. t-value P-value Estimate S.E. t-value P-value
Mean
Constant 6.8667 1.0012 6.858 <0.0001 6.7778 0.9853 6.879 <0.0001
Age (x1) -0.0627 0.0178 -3.525 0.0006 -0.0617 0.0174 -3.550 0.0006
BMI (x2) -0.1512 0.0367 -4.122 <0.0001 -0.1475 0.0361 -4.087 <0.0001
AGE*BMI 0.0020 0.0006 3.067 0.0027 0.0020 0.0006 3.214 0.0017
Leptin (x6) 0.0217 0.0184 1.179 0.2409 0.0282 0.0180 1.566 0.1202
Resistin (x8) -0.0701 0.0296 -2.371 0..0195 -0.0662 0.0289 -2.293 0.0237
BMI*Resistin 0.0020 0.0010 2.003 0.0476 0.0018 0.0010 1.886 0.0615
BMI*Leptin -0.0006 0.0006 -0.976 0.3312 -0.0008 0.0006 -1.372 0.1729
Dispersion
Constant -2.325 0.6674 -3.483 0.0007 -2.318 0.6595 -3.515 0.0006
Age (x1) 0.019 0.0114 1.690 0.0939 0.017 0.0112 1.553 0.1233
AIC 673.8 673.368
Table 4. Results for mean & dispersion models for Resistin from Log-Normal and Gamma fit
Model Covariates
Gamma fit Log-normal fit
Estimate s.e. t-value P-value estimate s.e. t-value P-value
Mean
Constant 1.6651 0.7909 2.105 0.0377 2.0242 0.81494 2.484 0.0146
Age (x1) -0.0052 0.0033 -1.547 0.1249 -0.0063 0.00345 -1.817 0.0721
Leptin (x6) -0.0306 0.0226 -1.352 0.1793 -0.0256 0.02334 -1.097 0.2751
Adiponectin (x8) 0.0888 0.0553 1.607 0.1111 0.0483 0.05623 0.860 0.3917
MCP-1 (x9) 0.0007 0.0001 4.402 <0.0001 0.0007 0.00015 4.253 <0.0001
Patient’s typ (Fx10) 0.5421 0.1084 4.999 <0.0001 0.4341 0.11120 3.904 0.0001
HOMA-IR (x5) -0.1087 0.0593 -1.832 0.0698 -0.1026 0.06124 -1.675 0.0969
Age*HOMA-IR 0.0015 0.0009 1.631 0.1059 0.0016 0.00096 1.637 0.1046
BMI (x2) -0.0028 0.0175 -0.158 0.8747 -0.0003 0.01808 -0.015 0.9880
Leptin*BMI 0.0014 0.0007 2.064 0.0415 0.0011 0.00072 1.529 0.1293
Glucose (x3) 0.0068 0.0062 1.084 0.2808 0.0030 0.00650 0.456 0.6493
Adiponectin*Glucose -0.0010 0.0006 -1.656 0.1007 -0.0006 0.00061 -1.000 0.3196
Leptin*Adiponectin -0.0009 0.0005 -1.807 0.0736 -0.0006 0.00052 -1.180 0.2407
Dis-
per-sion
Constant -4.8464 1.7259 -2.808 0.0059 -4.6565 1.8505 -2.516 0.0134
Leptin (x6) 0.0129 0.0091 1.427 0.1566 0.0124 0.0088 1.412 0.1609
Patient’s typ (Fx10) 0.7971 0.3097 2.574 0.0114 0.8184 0.3140 2.606 0.0105
BMI (x2) 0.1090 0.0645 1.689 0.0942 0.1081 0.0690 1.567 0.1201
Adiponectin (x7) 0.1885 0.1468 1.284 0.2020 0.1771 0.1542 1.149 0.2532
BMI*Adiponectin -0.0083 0.0058 -1.444 0.1518 -0.0081 0.0060 -1.342 0.1825
AIC 729.369 731.2
Biomarker resistin analysis is given by Das and Lee [22], 
and for ready reference it is reproduced in Table 4. Fitted 
resistin  mean & dispersion models are as follows:
Resistin Gamma fitted mean ( µ̂ ) model (from Table 4) is
µ̂ = exp( 1.6651 - 0.0306 Leptin - 0.0052 Age + 
0.0888 Adiponectin  + 0.5421 TYOP - 0.1087 HOMA-IR+ 
0.0007 MCP-1 + 0.0015 Age*HOMA-IR - 0.0028 BMI 
+ 0.0068 Glucose + 0.0014 BMI*Leptin - 0.0010 Glu-
cose*Adiponectin - 0.0009 Leptin*Adiponectin),  
and Resistin Gamma fitted variance ( 2σ̂ )  model (from 
Table 4) is   
2σ̂ = exp(- 4.8464 + 0.7971 TYOP + 0.1090 BMI + 
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Table 5. Associations of leptin with BMI, diabetes, age and breast cancer biomarkers
Response Associated with Types  of association P-value
Leptin mean
BMI (x2) Directly <0.0001
Glucose (x3) Directly 0.0135
Insulin (x4) Directly 0.0557
Adiponectin (x7) Directly 0.0110




Age (x1) Directly 0.0034
Resistin (x8) Directly 0.0028
Age*Resistin Inversely 0.0009
Biomarker leptin analysis is given by Das and Lee [23], 
and for ready reference it is reproduced in Table 5. Fitted 
leptin  mean & dispersion models are as follows:
Leptin Gamma fitted mean ( µ̂ ) model (from Table 5) 
is
µ̂ = exp( -0.227 + 0.092 BMI + 0.006 Glucose + 0.010 
Insulin + 0.025 Adiponectin + 0.016 Resistin - 0.001 
MCP.1 - 0.001 Adiponectin*Resistin), 
and Leptin Gamma fitted variance ( 2σ̂ )  model (from 
Table 5) is   
2σ̂ =  exp(-3.809 + 0.042 Age + 0.153 Resistin - 0.003 
Age*Resistin).     
3. Results
In Table 1, it is shown that mean BMI is directly associat-
ed with leptin (P<0.0001) and MCP-1 (P=0.0002), while 
it is inversely associated with adiponectin (P=0.0003), 
HOMA-IR (P<0.0001), and it is higher for healthy wom-
en (P=0.0116) than breast cancer women. In addition, 
variance of BMI is inversely associated with resistin 
(P=0.1450). On the other hand, from Table 2, mean MCP-
1 is directly associated with BMI (P<0.0001). In Table 3, 
it is shown that mean adiponectin is inversely associated 
with BMI (P<0.0001), BMI*Leptin (P=0.1729), while 
it is directly associated with Age*BMI (P=0.0017) and 
BMI*Resistin (P=0.0615). From Table 4, it is noted that 
mean resistin is directly associated with BMI*Leptin 
(P=0.0415), while its variance is directly associated 
with BMI (P=0.0942), and it is inversely associated with 
BMI*Adiponectin (P=0.1518). In Table 5, it is shown that 
mean leptin is directly associated with BMI (P<0.0001). 
4. Discussion
The summarized analyses of BMI, MCP-1, adiponection, 
resistin and lepin are given in Tables (1-5). From Table 1, 
mean BMI is directly associated with leptin (P<0.0001), 
or MCP-1 (P=0.0002), concluding that it increases as 
leptin, or MCP-1 rises. In addition, it is inversely as-
sociated with adiponectin (P=0.0003), or  HOMA-IR 
(P<0.0001), interpreting that it increases as adiponectin, 
or HOMA-IR  decreases. Mean BMI is inversely associ-
ated with patient types (P=0.0116), indicating that BMI 
is higher for healthy women than breast cancer women. 
Variance of BMI is partially inversely associated with re-
sistin (P=0.1450), interpreting that BMI variance rises as 
resistin level decreases. It is noted that partially significant 
effect is treated as confounder in epidemiology. 
From  Table 2,  it is observed that MCP-1 is directly as-
sociated with BMI (P<0.0001), indicating that it increases 
as BMI increases. This is also observed from the BMI 
model as stated above.  From Table 3, it is noted that mean 
adiponectin is inversely associated with BMI (P<0.0001), 
indicating that it decreases as BMI rises. This is also ob-
served from BMI model. Mean adiponectin is directly as-
sociated with BMI*Resistin (P=0.0615), concluding that 
it rises as the interaction effect BMI*Resistin increases. 
In addition, mean adiponectin is inversely associated with 
BMI*Leptin (P=0.1729), indicating that it decreases as 
BMI*Leptin rises. Moreover, mean adiponectin is directly 
associated with Age*BMI (P=0.0017), concluding that 
it rises as the interaction effect Age*BMI increases. This 
implies that over weight women at older ages have higher 
level of adiponectin. From Table 4, mean resistin is direct-
ly associated with the interaction effect of BMI*Leptin 
(P=0.0415), concluding that it rises as interaction effect 
of BMI*Leptin increases. Variance of resistin is directly 
associated with BMI (P=0.0942), interpreting that it in-
DOI: https://doi.org/10.30564/jor.v2i1.2007
6
Journal of Oncology Research | Volume 02 | Issue 01 | January 2020
Distributed under creative commons license 4.0
creases as BMI increases. Variance of resistin is inversely 
associated with BMI*Adiponectin (P=0.1518), indicating 
that it rises as BMI*Adiponectin decreases. From Table 5, 
mean leptin is directly associated with BMI (P<0.0001), 
indicating that it rises as BMI rises. This is also observed 
in BMI model. All the above summarized associations be-
tween BMI and BCBs are displayed in Table 6.
Table 6. Associations between BMI & breast cancer bio-
markers
Model Response Associated with Association types P-vale
Mean BMI (x2)
Leptin (x6) Directly <0.0001
Adiponectin (x7) Negative 0.0003
MAC-1 (x9) Directly 0.0002
HOMA-IR (x5) Inversely <0.0001
Patient’s type 
(Fx10) Inversely 0.0116
Dispersion Resistin (x8) Inversely 0.1450






BMI (x2) Directly 0.0942
BMI*
Adiponectin Inversely 0.1518
Mean Leptin (x6) BMI (x2) Directly <0.0001
Mean Adiponec-tin (x7)




The present derived associations between BMI and 
BCBs are little compared with the previous findings as 
the earlier research articles have not considered all these 
BCBs along with BMI. In addition, the earlier articles 
have not considered probabilistic joint modeling to derive 
these associations. All these reported results herein are 
only based on the articles [19-23].      
5. Conclusions
The report examines the associations between BMI and 
BCBs such as MCP-1, leptin, adiponection and resistin. 
These associations are reported herein considering the 
models of BMI and each BCB. From these models, it 
can be concluded that BMI and BCBs are associated 
in both mean and variance models. BMI increases as 
leptin, or MCP-1 increases, or adiponection, or resistin, 
or HOMA-IR decreases. Many interaction effects such as 
BMI*Leptin and BMI*Adiponectin are associated with 
resistin, while  BMI*Resistin, BMI*Leptin and Age*BMI 
are associated with adiponectin.  The report gives clear 
associations between BMI and BCBs which are very help-
ful to the researchers and medical practitioners. Medical 
practitioners and women should care on BMI along with 
breast cancer biomarkers.
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